You are here: HomeSolutionsIndustriesConsumer Health
print my pages

Country Report

Consumer Health in Ireland

Jun 2012

Price: US$2,400

About this Report

EXECUTIVE SUMMARY

Consumer health remains positive

Consumer health in Ireland continued to have a strong performance of 4% in 2011, despite on-going economic worries combined with lower levels of disposable income and reduced consumer spending. While a recovery is in evidence, it is export-driven and very little changed from the consumer’s perspective, resulting in value for money remaining the most important factor in purchasing decisions. However, the very high levels of price promotions and discounting witnessed in previous years eased as a result of consumer weariness of the tactic. Consumers continue to be price-conscious but are striving to achieve real, long term savings.

New guidance for OTC paediatric cough/cold remedies for children under six

The Irish Medicines Board (IMB) reviewed the safety and efficacy of OTC paediatric cough/cold remedies authorised for use in children between two to six years of age. In a letter issued to pharmacists in September 2011, the IMB cited that “the risk-benefit balance in this age group has not been shown to be favourable”. Furthermore, there was evidence of links between these products and allergic reactions and drowsiness in children. However, advice for children aged six to 12 years remains unchanged. The IMB noted the recommendations “reflect an evolution in therapeutic strategy over time rather than as a result of any new or specific development”.

Government cuts encourage OTC sales

The Irish Government and Department of Health continue to reduce the percentage of reimbursement to pharmacists for prescribed medicines. The result was to further discourage the medical profession from prescribing unnecessary items and to encourage sales of over the counter products as doctors are more likely to recommend these. Furthermore, there is an expectation that there will be more Rx to OTC switches in the forecast period as part of the cost cutting efforts of The Health Service Executive (HSE) which was charged with reducing costs to the Exchequer by 35% by 2015. It is likely that low strength statins and eye ointments may be amongst those coming under consideration. This changing attitude was reinforced by a radio campaign encouraging citizens to visit their pharmacist before incurring the expense of a visit to the doctor's surgery in order to get free advice about minor ailments.

Pharmacy-led sales dominate channels

A large proportion of consumer health products in Ireland are pharmacy-only products, however many of the 15,000 community pharmacies also provide an extensive range of other consumer health products. The pharmacies are represented by well-trained, highly informed staff capable of offering professional advice and opinion on products. This resulted in health and beauty retailers, comprising chemists/pharmacies (42%), parapharmacies/drugstores (21%) and other healthcare specialists (less than 1%) continuing to enjoy the majority of value coverage for consumer health in Ireland. Due to this difference in availability of products and the professionalism and level of care offered in these outlets, other channels continue to struggle to maintain market share.

Forecast performance expected to be muted

Although forecast performance is expected to be positive it is also expected to be at a more subdued rate than during the review period. This is not surprising given the changed economic conditions for Ireland and the rest of the West. Ireland faces a long road to recovery and while initial signals are promising, any recovery will be export-led, with domestic growth lagging behind. Consumer spending is expected to remain cautious and unemployment to remain high for some time. Government moves to reduce costs to the consumer by allowing generic substitution and the possibility of increased levels of Rx to OTC switches may serve to improve both volume and value sales.


Samples (FAQs about samples):

doc_pdf.png Sample Consumer Health Market Research Report

doc_excel_table.png Sample Consumer Health Data

Delivery: Files are delivered directly into your account within a few minutes of purchase.

Overview

Discover the latest market trends and uncover sources of future market growth for the Consumer Health industry in Ireland with research from Euromonitor's team of in-country analysts.

Find hidden opportunities in the most current research data available, understand competitive threats with our detailed market analysis, and plan your corporate strategy with our expert qualitative analysis and growth projections.

If you're in the Consumer Health industry in Ireland, our research will save you time and money while empowering you to make informed, profitable decisions.

When you purchase this report, you also get the data and the content from these category reports in Ireland for free:

The Consumer Health in Ireland market research report includes:

  • Analysis of key supply-side and demand trends
  • Detailed segmentation of international and local products
  • Historic volumes and values, company and brand market shares
  • Five year forecasts of market trends and market growth  
  • Robust and transparent market research methodology, conducted in-country

Our market research reports answer questions such as:

  • What is the market size of Consumer Health in Ireland?
  • What are the major brands in Ireland?
  • What are the main trends in OTC Healthcare?

Why buy this report?

  • Gain competitive intelligence about market leaders
  • Track key industry trends, opportunities and threats
  • Inform your marketing, brand, strategy and market development, sales and supply functions

This industry report originates from Passport, our Consumer Health market research database.

Table of Contents

Table of Contents

Consumer Health in Ireland - Industry Overview

EXECUTIVE SUMMARY

Consumer health remains positive

New guidance for OTC paediatric cough/cold remedies for children under six

Government cuts encourage OTC sales

Pharmacy-led sales dominate channels

Forecast performance expected to be muted

KEY TRENDS AND DEVELOPMENT

Difficult economic conditions persist

Your health is your wealth

Cost cutting may lead to increased switching

Value remains key for consumers

MARKET INDICATORS

  • Table 1 Consumer Expenditure on Health Goods and Medical Services 2006-2011
  • Table 2 Life Expectancy at Birth 2006-2011

MARKET DATA

  • Table 3 Sales of Consumer Health by Category: Value 2006-2011
  • Table 4 Sales of Consumer Health by Category: % Value Growth 2006-2011
  • Table 5 Consumer Health Company Shares 2007-2011
  • Table 6 Consumer Health Brand Shares 2008-2011
  • Table 7 Penetration of Private Label by Category 2006-2011
  • Table 8 Sales of Consumer Health by Distribution Format: % Analysis 2006-2011
  • Table 9 Sales of Consumer Health by Category and Distribution Format: % Analysis 2011
  • Table 10 Forecast Sales of Consumer Health by Category: Value 2011-2016
  • Table 11 Forecast Sales of Consumer Health by Category: % Value Growth 2011-2016

APPENDIX

OTC registration and classification

Prescription-only classification

Controlled drugs

OTC consumer health products

Restrictions on the sale of acetaminophen products

Restrictions on the sale of codeine products

De-listing and de-reimbursement

Switching and reimbursable status

Advertising

Manufacturers seek greater freedom in advertising prescription-only products

Self-regulation

Packaging and labelling

Distribution

Distance selling remains prohibited, while imports for personal use remain legal

Vitamins and dietary supplements registration and classification

Restrictions on the sale of products containing vitamin or mineral ingredients

EU Legislation

Self-medication/self-care and preventative medicine

Generics

Switches

  • Summary 1 OTC - Switches 2009-2011

SOURCES

  • Summary 2 Research Sources

Consumer Health in Ireland - Company Profiles

Beeline Healthcare Ltd in Consumer Health (Ireland)

STRATEGIC DIRECTION

KEY FACTS

COMPANY BACKGROUND

COMPETITIVE POSITIONING

  • Summary 4 Beeline Healthcare Ltd: Competitive Position 2011

Pharma Nord ApS in Consumer Health (Ireland)

STRATEGIC DIRECTION

KEY FACTS

COMPANY BACKGROUND

COMPETITIVE POSITIONING

  • Summary 6 Pharma Nord ApS : Competitive Position 2011

Pinewood Healthcare Group in Consumer Health (Ireland)

STRATEGIC DIRECTION

KEY FACTS

COMPANY BACKGROUND

  • Summary 8 Pinewood Healthcare Group: Production Statistics 2011

COMPETITIVE POSITIONING

  • Summary 9 Pinewood Healthcare Group: Competitive Position 2011

Seven Seas Ireland Ltd in Consumer Health (Ireland)

STRATEGIC DIRECTION

KEY FACTS

COMPANY BACKGROUND

PRODUCTION

COMPETITIVE POSITIONING

  • Summary 11 Seven Seas Ireland Ltd: Competitive Position 2011

Sona Nutrition Ltd in Consumer Health (Ireland)

STRATEGIC DIRECTION

KEY FACTS

COMPANY BACKGROUND

  • Summary 13 Sona Nutrition Ltd Production Statistics 2011

COMPETITIVE POSITIONING

  • Summary 14 Sona Nutrition Ltd: Competitive Position 2011

Adult Mouth Care in Ireland - Category Analysis

HEADLINES

TRENDS

  • Although difficult economic conditions continued to discourage many Irish consumers from expensive dental visits, which can cost from €70 for a standard checkup, and to practice better dental hygiene, it also had the effect of encouraging consumers to purchase less expensive products which were perceived to be better value for money. Many of these products fell outside the scope of adult mouth care in consumer health such as mouthwashes, etc.

SWITCHES

COMPETITIVE LANDSCAPE

  • Reckitt Benckiser Ireland leads company sales in 2011 with 37% value share. The company fully amalgamated former SSL International brand Anbesol Anaesthetic Antiseptic, which has the leading position with 21% value share. As a result, it doubled its share in adult mouth care and took lead position from GlaxoSmithKline Ireland. This latter company increased its value share to 21% thanks to continued strong performance of its Corsodyl brand, which increased value share to 20% in 2011.

PROSPECTS

  • Adult mouth care is expected to have a CAGR of 1% over the forecast period. Although the growth of other popular oral care brands, such as Listerine, is expected to reduce the growth of adult mouth care, rising rates of self-medication may help to offset the sales lost to less expensive, substitute products.

CATEGORY DATA

  • Table 12 Sales of Adult Mouth Care: Value 2006-2011
  • Table 13 Sales of Adult Mouth Care: % Value Growth 2006-2011
  • Table 14 Adult Mouth Care Company Shares by Value 2007-2011
  • Table 15 Adult Mouth Care Brand Shares by Value 2008-2011
  • Table 16 Forecast Sales of Adult Mouth Care: Value 2011-2016
  • Table 17 Forecast Sales of Adult Mouth Care: % Value Growth 2011-2016

Analgesics in Ireland - Category Analysis

HEADLINES

TRENDS

  • August 2010 saw the Pharmacy Society of Ireland (PSI) introduce guidelines which restricted the display and sale of codeine-based products in pharmacies in Ireland with window displays prohibited and products held in the dispensary area, out of sight of the public, rather than on display behind the counter. Pharmacists are required to make consumers requesting the products aware of the types of pain addressed by the products and the addictive nature of codeine. Furthermore, pharmacists advise alternative acetaminophen- or ibuprofen-based products, encouraging use of these products over codeine-based products. This resulted in a dramatic decline in growth rates within combination products which grew by only 1% in 2011 compared to 7% in 2010 and 10% in 2009. The most popular codeine-based product in Ireland, GlaxoSmithKline Ireland Ltd’s Solpadeine, fell from its leading position in combination products in 2010. It had further decline in 2011 to hold 35% value share behind Reckitt Benckiser Ireland Ltd’s Nurofen Plus, which increased value share to 40% in 2011. However, within analgesics overall the positioning of the top three brands remained unchanged in 2011.

SWITCHES

COMPETITIVE LANDSCAPE

  • GlaxoSmithKline (Ireland) Ltd leads company sales in 2011 with 33% value share of analgesics due to the performance of its top brands Panadol, Solpadeine and Disprin. However, this is a reduced share compared to 2010. Reckitt Benckiser Ireland Ltd had strong performance of brands such as Nurofen, which retained top position with an increased value share of 22%. This, combined with sales from the amalgamation of former SSL International Plc brands, resulted in the company’s value share increasing by two percentage points to 29% in 2011. This brought the company to within four percentage points of GlaxoSmithKline (Ireland) Ltd’s leading position.

PROSPECTS

  • Analgesics is expected to achieve a CAGR of 3% over the forecast period to 2016, driven by Diclofenac with expected CAGR of 7% and paediatric combination products with an expected CAGR of 6%. However, Diclofenac growth is from a very low base of €600,000, which is expected to reach €800,000 by 2016. Aspirin is expected to see negative growth of -2% as consumers continue to favour other forms of pain relief viewed as being more effective.

CATEGORY DATA

  • Table 18 Sales of Analgesics by Category: Value 2006-2011
  • Table 19 Sales of Analgesics by Category: % Value Growth 2006-2011
  • Table 20 Topical Analgesics/Anaesthetic by Format: % Value Breakdown 2006-2011
  • Table 21 Analgesics Company Shares by Value 2007-2011
  • Table 22 Analgesics Brand Shares by Value 2008-2011
  • Table 23 Forecast Sales of Analgesics by Category: Value 2011-2016
  • Table 24 Forecast Sales of Analgesics by Category: % Value Growth 2011-2016

Calming and Sleeping in Ireland - Category Analysis

HEADLINES

TRENDS

  • Calming and sleeping has the highest percentage of herbal/traditional products in consumer health with 89%. No OTC medicinal products were licensed for use as a sleep aid in Ireland in 2011, which explains the uniquely high share for herbal/traditional products.

SWITCHES

COMPETITIVE LANDSCAPE

  • Bach Flower Remedies leads both company and brand sales with 25% value share of calming and sleeping, closely followed by Chefaro Ireland Ltd which increased value share to 24% in 2011.

PROSPECTS

  • Calming and sleeping in Ireland is expected to continue to perform well over the forecast period, as Irish consumers’ lives become more hectic and stressful. It is expected to see a constant value CAGR of 5% to reach €5 million by 2016.

CATEGORY DATA

  • Table 25 Sales of Calming and Sleeping: Value 2006-2011
  • Table 26 Sales of Calming and Sleeping: % Value Growth 2006-2011
  • Table 27 Calming and Sleeping Company Shares by Value 2007-2011
  • Table 28 Calming and Sleeping Brand Shares by Value 2008-2011
  • Table 29 Forecast Sales of Calming and Sleeping: Value 2011-2016
  • Table 30 Forecast Sales of Calming and Sleeping: % Value Growth 2011-2016

Cough, Cold and Allergy (Hay Fever) Remedies in Ireland - Category Analysis

HEADLINES

TRENDS

  • The IMB reviewed the safety and efficacy of OTC cough and cold medicines authorised for use in children between 2-6 years of age. In a letter issued to pharmacists in September 2011, the IMB cited that “the risk-benefit balance in this age group has not been shown to be favourable”. Furthermore, there was some evidence of links between these products and allergic reactions and drowsiness in children. Advice for children aged 6 to 12 years remains unchanged, however, as the incidence of coughs and colds reduces as age increases, while tolerance increases with the child’s size. Further, it is felt that older children can better articulate if the product is having any benefit or indeed unwanted effect, so that the advice is these products should continue to be used as necessary, up to daily recommended allowances. The IMB noted that recommendations reflect an evolution in therapeutic strategy over time rather than as a result of any new or specific development.

SWITCHES

COMPETITIVE LANDSCAPE

  • Reckitt Benckiser Ireland leads company sales in Ireland in 2011 with 26% value share, followed closely by McNeil Healthcare (Ireland) Ltd with 23% value share. The latter's product range was comprised largely of the Benylin brand which maintains an overall value share of 19% in 2011. The continued strong performance of Reckitt Benckiser Ireland is thanks to the Strepsils and Lemsip brands which have a strong 10% and 9% value share to reach second and third places respectively in brand shares in 2011.

PROSPECTS

  • Cough, cold and allergy (hay fever) remedies is expected to have a CAGR of 2% over the forecast period to 2016. Although there is evidence of a return to growth for the Irish economy this is export-driven and internally Ireland remains in recessionary conditions as consumer spending remains low. Given the expected severe and restrictive budgets necessary for Ireland to remain on track with EU/IMF bailout conditions it may prove difficult to stimulate growth beyond this level.

CATEGORY DATA

  • Table 31 Sales of Cough, Cold and Allergy (Hay Fever) Remedies by Category: Value 2006-2011
  • Table 32 Sales of Cough, Cold and Allergy (Hay Fever) Remedies by Category: % Value Growth 2006-2011
  • Table 33 Sales of Decongestants by Category: Value 2006-2011
  • Table 34 Sales of Decongestants by Category: % Value Growth 2006-2011
  • Table 35 Sales of Paediatric Cough, Cold and Allergy (Hay Fever) Remedies by Category: Value 2006-2011
  • Table 36 Sales of Paediatric Cough, Cold and Allergy (Hay Fever) Remedies by Category: % Value Growth 2006-2011
  • Table 37 Cough, Cold and Allergy (Hay Fever) Remedies Company Shares by Value 2007-2011
  • Table 38 Cough, Cold and Allergy (Hay Fever) Remedies Brand Shares by Value 2008-2011
  • Table 39 Forecast Sales of Cough, Cold and Allergy (Hay Fever) Remedies by Category: Value 2011-2016
  • Table 40 Forecast Sales of Cough, Cold and Allergy (Hay Fever) Remedies by Category: % Value Growth 2011-2016

Digestive Remedies in Ireland - Category Analysis

HEADLINES

TRENDS

  • Value sales within digestive remedies continued to be impacted by ongoing economic difficulties in Ireland as consumer spending remained extremely low, with severe cutbacks in non-essential spending. Value sales were further impacted by increased use of generic products. However, the introduction of proton pump inhibitors to the OTC market in 2010 provided a boost to value sales.

SWITCHES

COMPETITIVE LANDSCAPE

  • McNeil Healthcare (Ireland) leads in 2011 with 29% value share of digestive remedies. The share is made up of a range of products including Motilium, which takes third place in leading brands, Pepcid, Arret, Imodium and Imodium Plus. The leading brands, however, are Gaviscon (17%) by Reckitt Benckiser Ireland which is in second position in company rankings, and Rennie (15%) by Bayer Ltd.

PROSPECTS

  • Digestive Remedies is expected to achieve a CAGR of 1% over the forecast period to 2016. Self-medication is expected to continue to increase over the forecast period. This is due to the ongoing recession and reduced consumer spending, meaning less frequent visits to doctors but also due to increased awareness of health and wellness, aiding growth within digestive remedies. Sales of motion sickness remedies are expected to slow down, because Irish people are not travelling to the same extent as previous years. While growth in paediatric laxatives is expected to continue to decline, overall value is expected to remain constant.

CATEGORY DATA

  • Table 41 Sales of Digestive Remedies by Category: Value 2006-2011
  • Table 42 Sales of Digestive Remedies by Category: % Value Growth 2006-2011
  • Table 43 Digestive Remedies Company Shares by Value 2007-2011
  • Table 44 Digestive Remedies Brand Shares by Value 2008-2011
  • Table 45 Forecast Sales of Digestive Remedies by Category: Value 2011-2016
  • Table 46 Forecast Sales of Digestive Remedies by Category: % Value Growth 2011-2016

Ear Care in Ireland - Category Analysis

HEADLINES

TRENDS

  • Ear care products were used to treat two conditions: ear wax build-up and external canal infections (otitis externa), also known as swimmers ear. Products positioned to treat ear wax build-up were also used as a preventative measure in patients prone to wax build-up.

SWITCHES

COMPETITIVE LANDSCAPE

  • Both company and brand shares were significantly restructured since 2010 as a result of the exclusion of brands previously included.

PROSPECTS

  • Ear care is expected to see minimal growth over the forecast period to 2016 with value sales remaining stagnant. Further growth is only likely to occur as a result of significant investment by manufacturers into new or improved products and formulations. Given the economic conditions in 2011, both domestic and international, this is unlikely to occur.

CATEGORY DATA

  • Table 47 Sales of Ear Care: Value 2006-2011
  • Table 48 Sales of Ear Care: % Value Growth 2006-2011
  • Table 49 Ear Care Company Shares by Value 2007-2011
  • Table 50 Ear Care Brand Shares by Value 2008-2011
  • Table 51 Forecast Sales of Ear Care: Value 2011-2016
  • Table 52 Forecast Sales of Ear Care: % Value Growth 2011-2016

Emergency Contraception in Ireland - Category Analysis

HEADLINES

TRENDS

  • In January 2011, Boots Retail Ireland Ltd announced that it would begin supplying emergency contraception without prescription. This was due to a provision found in the amendment to legislation in 2005 relating to emergency contraception, which states that emergency contraception can be offered by "qualified medical professionals" under protocols set out by a medical professional such as a doctor. Boots stores began offering the morning after pill, Levonelle, one of two products available in Ireland, at a cost of €45 including a consultation in January 2011.

COMPETITIVE LANDSCAPE

  • As it is the only product available over the counter since February 2011, NorLevo leads brand sales in 2011, accounting for 90% of value sales.

PROSPECTS

  • Emergency contraception is expected to have CAGR of 2% over the forecast period to 2016. As women become more aware of the availability of the product’s OTC status it is likely that sales will continue to increase over the forecast period. However, the strong religious beliefs held by a significant (though declining) percentage of Ireland’s population and a reluctance to trust pharmacists in some instances may limit growth slightly.

CATEGORY DATA

  • Table 53 Sales of Emergency Contraception: Value 2011
  • Table 54 Sales of Emergency Contraception: % Value Growth 2011
  • Table 55 Emergency Contraception Company Shares by Value 2007-2011
  • Table 56 Emergency Contraception Brand Shares by Value 2008-2011

Eye Care in Ireland - Category Analysis

HEADLINES

TRENDS

  • 2011 saw lower than expected performance of allergy eye care products in Ireland. Due to poor summer weather, products aimed at seasonal allergies such as hayfever did not perform as well as expected by manufacturers as people spent less time outdoors and pollen levels remained lower than usual. This situation improved slightly towards the end of the summer season, especially during August and September when weather conditions improved. This was unusual for Ireland where the hayfever season generally runs from the end of May until the beginning to mid August. There was an extension to this period with symptoms beginning as early as March. Performance was further impacted by fewer numbers of people working outdoors, for example within the construction industry, which continued to contract.

SWITCHES

COMPETITIVE LANDSCAPE

  • Reckitt Benckiser Ireland leads company sales with 36% value share in 2011. The company’s Optrex brand remains popular amongst Irish consumers, with a high level of brand recognition. Sanofi Ireland is second with a 21% value share thanks to its highly popular Brolene (12%) and Opticrom (9%) brands.

PROSPECTS

  • Eye care is expected to have a CAGR of 2% over the forecast period. Its performance will be positively impacted by the more general use of products, however this will be restricted by reduced consumer spending on non-essential items in the early years of the forecast period. Allergy eye care, meanwhile, will continue to perform well due to the perceived necessity of use among many consumers.

CATEGORY DATA

  • Table 57 Sales of Eye Care by Category: Value 2006-2011
  • Table 58 Sales of Eye Care by Category: % Value Growth 2006-2011
  • Table 59 Standard Eye Care by Format: % Value Breakdown 2007-2011
  • Table 60 Standard Eye Care by Positioning: % Value Breakdown 2007-2011
  • Table 61 Eye Care Company Shares by Value 2007-2011
  • Table 62 Eye Care Brand Shares by Value 2008-2011
  • Table 63 Forecast Sales of Eye Care by Category: Value 2011-2016
  • Table 64 Forecast Sales of Eye Care by Category: % Value Growth 2011-2016

Herbal/Traditional Products in Ireland - Category Analysis

HEADLINES

TRENDS

  • Restricted consumer spending continued to impact herbal/traditional products in 2011. With the cost of many herbal/traditional products at a premium compared with their standard counterparts, many Irish consumers reconsidered their purchasing. However, Irish consumers’ continuing interest in natural products continued to encourage growth.

COMPETITIVE LANDSCAPE

  • Cadbury Ireland maintains its lead in herbal/traditional products with a value share of 16% in 2011. The competitive environment within herbal/traditional products in 2011 remained fragmented due to the wide range and scope of the products which fall under this classification. However, the prominent players included GR Lane Health Products Ltd with 6% value share, Seven Seas Ireland, Reckitt Benckiser Ireland, Chefaro Ireland and Sona Nutrition each with 5% value share.

PROSPECTS

  • Herbal/traditional products is expected to have a constant value CAGR of 1% over the forecast period to reach €37 million in 2016. The effective regulation of herbal/traditional products through the implementation of the the Medicinal Products (Prescription and Control of Supply) Regulations 2007 which came into effect on 23 July 2007 requires that no medicinal product can be placed on the market without being registered via a marketing authorisation or certificate of traditional-use registration. The regulations provided an exemption from this requirement until 30 April 2011 for herbal/traditional products on the market in Ireland prior to July 2007. This restriction will hinder new product development over the forecast period due to the time and cost involved in registering new products.

CATEGORY DATA

  • Table 65 Sales of Herbal/Traditional Products: Value 2006-2011
  • Table 66 Sales of Herbal/Traditional Products: % Value Growth 2006-2011
  • Table 67 Herbal/Traditional Products Company Shares 2007-2011
  • Table 68 Herbal/Traditional Products Brand Shares 2008-2011
  • Table 69 Forecast Sales of Herbal/Traditional Products: Value 2011-2016
  • Table 70 Forecast Sales of Herbal/Traditional Products: % Value Growth 2011-2016

Medicated Skin Care in Ireland - Category Analysis

HEADLINES

TRENDS

  • 2011 proved to be a poor year for topical allergy remedies/antihistamines with lower than expected growth of 2% as a result of poor summer weather. The lower than usual temperatures resulted in less insects and contributed to fewer outdoor activities, resulting in fewer insect bites and stings, which negatively impacted both volume and value sales. Although late summer weather improved, especially during September and early October, this was not enough to compensate for the lost sales earlier in the year.

SWITCHES

COMPETITIVE LANDSCAPE

  • McNeil Healthcare (Ireland) maintains its lead in medicated skin care with a 24% value share in 2011. The continued strong position of the company was due to the success of a variety of products such as Anusol, Rogaine and Daktarin which hold 8%, 5% and 2% value share respectively and are in third, fourth and ninth position respectively within medicated skin care. The leading brand, however, remains Canesten by Bayer Ltd which holds 12% value share. Canesten is the product most usually offered on prescription or recommended by doctors for treatment of vaginal fungal infections and OTC sales benefited from this.

PROSPECTS

  • Medicated skin care is expected to achieve a CAGR of 2% over the forecast period as it continues to mature. Furthermore, it is expected that the effects of Ireland's recession and reduced consumer spending will continue into the forecast period.

CATEGORY DATA

  • Table 71 Sales of Medicated Skin Care by Category: Value 2006-2011
  • Table 72 Sales of Medicated Skin Care by Category: % Value Growth 2006-2011
  • Table 73 Medicated Skin Care Company Shares by Value 2007-2011
  • Table 74 Medicated Skin Care Brand Shares by Value 2008-2011
  • Table 75 Hair Loss Treatments Brand Shares by Value 2008-2011
  • Table 76 Forecast Sales of Medicated Skin Care by Category: Value 2011-2016
  • Table 77 Forecast Sales of Medicated Skin Care by Category: % Value Growth 2011-2016

NRT Smoking Cessation Aids in Ireland - Category Analysis

HEADLINES

TRENDS

  • The Public Health (Tobacco) (Amendment) Act 2011enabled the Minister for Health to make regulations to introduce combined text and photo warnings on tobacco products. This was a further bid to raise and maintain awareness of the associated risks of smoking and hence to reduce the numbers of smokers and those taking up the habit in the first place. These regulations were being drafted in 2011 with implementation expected before the end of the year, or in early 2012 according to the Department of Health and Children (DOHC).

SWITCHES

COMPETITIVE LANDSCAPE

  • Nicorette from McNeil Healthcare (Ireland) leads NRT smoking cessation aids in 2011 with a 68% value share. The brand continues to successfully grow value share in NRT gum, however this is partially offset by continued losses in the second-largest category, NRT patches, although this is at a lower level than in 2010. Niquitin CQ Clear Patch from GlaxoSmithKline (Ireland) continues to post strong performances year on year and has 34% value share of NRT patches.

PROSPECTS

  • NRT smoking cessation aids is expected to have a CAGR of 1% to reach €23 million over the forecast period. The Irish government and the EU want to reduce smoking by making life more problematic for smokers, thereby encouraging them to quit due to tighter regulations and price increases on tobacco. Taxes on cigarettes, a popular means of increasing tax revenues with successive governments, remained unchanged in the December 2010 budget. The government cited the law of diminishing returns and concerns about potential increases in smuggling and subsequent impact on exchequer returns. However, with the Irish government under increasing pressure to increase tax revenues duty on cigarettes was increased by 0.25c per pack of 20 cigarettes. Continuing economic uncertainty and budget severity is likely to encourage more smokers to quit in the forecast period.Expected growth rates are lower than those seen over the review period mainly as a result of performances from NRT gum which is expected to see 0% CAGR over the forecast period. Growth within NRT lozenges is expected to remain stagnant as these products fail to gain favour with Irish consumers. NRT inhalators, however, will continue to return good positive growth with a CAGR of 3% to 2016, however, these rates of growth come from a low value base which is expected to reach €170,000 by 2016. NRT patches is expected to continue to remain popular amongst consumers as the most unobtrusive and easy to manage format with expected CAGR of 2% over the forecast period.

CATEGORY INDICATORS

  • Table 78 Number of Smokers by Gender 2006-2011

CATEGORY DATA

  • Table 79 Sales of NRT Smoking Cessation Aids by Category: Value 2006-2011
  • Table 80 Sales of NRT Smoking Cessation Aids by Category: % Value Growth 2006-2011
  • Table 81 NRT Gum Flavours: % Value Breakdown 2006-2011
  • Table 82 NRT Smoking Cessation Aids Company Shares by Value 2007-2011
  • Table 83 NRT Smoking Cessation Aids Brand Shares by Value 2008-2011
  • Table 84 Forecast Sales of NRT Smoking Cessation Aids by Category: Value 2011-2016
  • Table 85 Forecast Sales of NRT Smoking Cessation Aids by Category: % Value Growth 2011-2016

Sports Nutrition in Ireland - Category Analysis

HEADLINES

TRENDS

  • The impact of Ireland’s recession and ongoing economic uncertainty on sales of sports nutrition products continued to be lower than that seen in other retail markets. As health and wellness continued to grow in importance, levels of participation in a wide variety of sports increased, with a growing number of competitive events, especially at amateur level, becoming a key driver of sales.

COMPETITIVE LANDSCAPE

  • Maximuscle Ltd leads with 23% value share of sports nutrition. As the leading brand name within sports nutrition it is one which is well known and respected even by those with little knowledge of sports nutrition. Furthermore, unlike other companies, Maximuscle products are widely available through major healthfood shops around Ireland, as well as in gyms and via internet retailing. This gives the company a significant advantage over other manufacturers in terms of strong and varied distribution.

PROSPECTS

  • Sports nutrition is expected to achieve CAGR of 2% over the forecast period to 2016 driven by increased consumer interest. However, as reliable internet access increases and Irish consumers become more confident and comfortable with the security of making purchases online, it can be expected that this will provide further opportunities for growth.

CATEGORY DATA

  • Table 86 Sales of Sports Nutrition: Value 2006-2011
  • Table 87 Sales of Sports Nutrition: % Value Growth 2006-2011
  • Table 88 Sports Nutrition Company Shares 2007-2011
  • Table 89 Sports Nutrition Brand Shares 2008-2011
  • Table 90 Forecast Sales of Sports Nutrition: Value 2011-2016
  • Table 91 Forecast Sales of Sports Nutrition: % Value Growth 2011-2016

Vitamins and Dietary Supplements in Ireland - Category Analysis

HEADLINES

TRENDS

  • Since the onset of the recession in Ireland, vitamins and dietary supplements saw a large amount of discounting and promotional activity across the full range of channels as manufacturers and distributors sought to encourage volume sales, often at the expense of value sales, in a bid to retain brand presence and recognition. 2011, however, was marked by a reduction in the level of these promotions as a response to growing consumer apathy in these types of offers. Irish consumers were overwhelmed by special offers, BOGOF promotions, percentage discounting etc in all areas of consumer retailing in the review period. While initially successful in maintaining sales and encouraging consumers to spend, albeit at a lower rate than during the boom years, the tactic became dated with consumers beginning to feel they were no longer benefiting from promotions as much as before. This led them to reassess their criteria for seeking value for money, which remained the key purchasing factor for the majority of consumers.

Vitamins

Dietary Supplements

COMPETITIVE LANDSCAPE

  • Seven Seas Ireland continues to lead with a 28% value share in 2011, while Sona Nutrition and Bayer take second and third places respectively with value shares of 8% each in 2011. Seven Seas has a long-established, exceptionally strong brand image which is immediately recognisable by consumers. This is due to its presence in Ireland for more than 20 years and also to aggressive new product development and extensive marketing support all year round. Seven Seas Ireland held the leading position in fish oils and mineral supplements, with 56% and 40% value shares respectively in 2011. This was due to the strong sales of its Haliborange and Seven Seas Cod Liver Oil ranges. It also held the leading share of paediatric vitamins and dietary supplements. Furthermore, with its expansive portfolio of products, the company also had the highest value share of combination dietary supplements, single vitamins, garlic, ginseng, evening primrose oil and tonics and bottled nutritive drinks.

PROSPECTS

  • Vitamins and dietary supplements is expected to reach €63 million by 2016. Self-medication and health and wellness were key components of Irish consumer lifestyles and vitamins and dietary supplements, once viewed as a means of recuperation after illness or when in need of a tonic, are now accepted as being beneficial to health on an ongoing basis. This trend is expected to continue to strengthen over the forecast period, helping to maintain growth in vitamins and dietary supplements through increased penetration and higher frequency of use. However, continuing poor economic conditions will put pressure on disposable incomes, making consumers more mindful of their expenditure. As a result, price increases are expected to remain minimal, especially in the early years of the forecast period.

CATEGORY DATA

  • Table 92 Sales of Vitamins and Dietary Supplements by Category: Value 2006-2011
  • Table 93 Sales of Vitamins and Dietary Supplements by Category: % Value Growth 2006-2011
  • Table 94 Dietary Supplements by Positioning 2006-2011
  • Table 95 Vitamins and Dietary Supplements Company Shares by Value 2007-2011
  • Table 96 Vitamins and Dietary Supplements Brand Shares by Value 2008-2011
  • Table 97 Vitamins Brand Shares by Value 2008-2011
  • Table 98 Dietary Supplements Brand Shares by Value 2008-2011
  • Table 99 Forecast Sales of Vitamins and Dietary Supplements by Category: Value 2011-2016
  • Table 100 Forecast Sales of Vitamins and Dietary Supplements by Category: % Value Growth 2011-2016
  • Summary 15 Dietary Supplements: Brand Ranking by Positioning 2011.

Weight Management in Ireland - Category Analysis

HEADLINES

TRENDS

  • The much lauded OTC obesity product Alli by GlaxoSmithKline had a significant reversal of fortunes in 2011 as sales failed to match the company’s expectations. Demand for the product dropped so low that increasing numbers of retailers ceased stocking the product. Feedback from pharmacists indicated that consumers moved on to other products. Alli fell victim to the cycle of serial dieting in Ireland whereby consumers will try out a product but quickly move on once it is realised that it is not a miracle cure for weight problems.

COMPETITIVE LANDSCAPE

  • Allegro Holdings leads with 24% value share with the Slim Fast brand. The product range came under pressure in 2010 from OTC obesity product Alli, however the subsequent reduction in sales of the latter product resulted in Slim Fast regaining lost value share and maintaining its leading position in weight management in Ireland.

PROSPECTS

  • Weight management is expected to see a constant value CAGR of 1% over the forecast period to 2016 as the negative performance of Alli continues to limit the potential for category growth. Meal replacement slimming and weight loss supplements are both expected to have CAGR of 4% over the forecast period.

CATEGORY DATA

  • Table 101 Sales of Weight Management: Value 2006-2011
  • Table 102 Sales of Weight Management: % Value Growth 2006-2011
  • Table 103 Weight Management Company Shares 2007-2011
  • Table 104 Weight Management Brand Shares 2008-2011
  • Table 105 Forecast Sales of Weight Management: Value 2011-2016
  • Table 106 Forecast Sales of Weight Management: % Value Growth 2011-2016

Wound Care in Ireland - Category Analysis

HEADLINES

TRENDS

  • First aid kits products were not sold in large volumes in Ireland and this low uptake continued to limit growth, although many consumers may keep a small kit either at home or in their car. First aid kits that were bought for this purpose were a one-off purchase which was not repeated on a regular basis. The replenishment of the kit, when necessary, was undertaken as items were required, for example, replacing a used box of plasters or a single bandage. They were mainly sold in chemists/pharmacies and parapharmacies/drugstores channels, with smaller kits performing slightly better in the supermarkets channel, due to better price promotions.

COMPETITIVE LANDSCAPE

  • Beiersdorf Ireland leads sales with 32% value share due to the continued dominance of the Elastoplast brand in the Irish market, which comprises a variety of plaster formats suitable for most everyday requirements. Fleming Medical Ltd retains second position in 2011 with 9% value share and is the leading supplier of first aid kits for home and office use.

PROSPECTS

  • Wound care is expected to achieve a CAGR of 2% over the forecast period to 2016. While an easing of recessionary conditions and the associated improvement in disposable incomes may encourage spending on premium products, especially in relation to those aimed at younger children, the majority of consumers will continue to purchase the same types of products that they always have.

CATEGORY DATA

  • Table 107 Sales of Wound Care by Category: Value 2006-2011
  • Table 108 Sales of Wound Care by Category: % Value Growth 2006-2011
  • Table 109 Wound Care Company Shares by Value 2007-2011
  • Table 110 Wound Care Brand Shares by Value 2008-2011
  • Table 111 Forecast Sales of Wound Care by Category: Value 2011-2016
  • Table 112 Forecast Sales of Wound Care by Category: % Value Growth 2011-2016

Segmentation

Segmentation

This market research report includes the following:

  • Consumer Health
    • OTC
      • Adult Mouth Care
      • Analgesics
        • Systemic Analgesics
          • Adult Analgesics
            • Acetaminophen
            • Aspirin
            • Combination Products - Analgesics
            • Diclofenac
            • Dipyrone
            • Ibuprofen
            • Ketoprofen
            • Naproxen
          • Paediatric Analgesics
            • Paediatric Acetaminophen
            • Paediatric Aspirin
            • Paediatric Combination Products - Analgesics
            • Paediatric Diclofenac
            • Paediatric Dipyrone
            • Paediatric Ibuprofen
            • Paediatric Ketoprofen
            • Paediatric Naproxen
        • Topical Analgesics/Anaesthetic
      • Calming and Sleeping
      • Cough, Cold and Allergy (Hay Fever) Remedies
        • Antihistamines/Allergy Remedies (Systemic)
        • Paediatric Cough, Cold and Allergy Remedies
          • Paediatric Allergy Remedies
          • Paediatric Cough/Cold Remedies
        • Combination Products - Cough, Cold and Allergy (Hay Fever) Remedies
        • Cough Remedies
        • Decongestants
          • Nasal Sprays
          • Oral Decongestants
          • Inhalant Decongestants
          • Decongestant Rubs
          • Nasal Decongestant Drops
          • Nasal Decongestant Plasters
        • Medicated Confectionery
        • Pharyngeal Preparations
      • Digestive Remedies
        • Paediatric Digestive Remedies
          • Paediatric Diarrhoeal Remedies
          • Paediatric Indigestion and Heartburn Remedies
          • Paediatric Laxatives
          • Paediatric Motion Sickness Remedies
        • Diarrhoeal Remedies
        • IBS Treatments
        • Indigestion and Heartburn Remedies
          • Antacids
          • Antiflatulents
          • Digestive Enzymes
          • H2 Blockers
          • Proton Pump Inhibitors
        • Laxatives
        • Motion Sickness Remedies
      • Ear Care
      • Emergency Contraception
      • Eye Care
        • Allergy Eye Care
        • Standard Eye Care
      • Medicated Skin Care
        • Medicated Shampoos
        • Topical Antifungals
        • Vaginal Antifungals
        • Hair Loss Treatments
        • Nappy (Diaper) Rash Treatments
        • Antiparasitics/Lice (Head and Body) Treatments
        • Antipruritics
        • Paediatric Medicated Skin Care
        • Cold Sore Treatments
        • Haemorrhoid Treatments
        • Topical Allergy Remedies/Antihistamines
        • Topical Germicidals/Antiseptics
      • NRT Smoking Cessation Aids
        • NRT Gum
        • NRT Inhalators
        • NRT Lozenges
        • NRT Patches
        • Other NRT
      • OTC Triptans
      • Wound Care
        • First Aid Kits
        • Sticking Plasters/Adhesive Bandages
        • Gauze, Tape and Other Wound Care
    • Sports Nutrition
      • Protein Products
        • Bars
        • Powder
        • RTD
        • Other Protein
      • Non-Protein Products
    • Vitamins and Dietary Supplements
      • Paediatric Vitamins and Dietary Supplements
      • Dietary Supplements
        • Combination Dietary Supplements
        • Herbal/Traditional Dietary Supplements
          • Combination Herbal/Traditional Dietary Supplements
          • Echinacea
          • Evening Primrose Oil
          • Garlic
          • Ginkgo Biloba
          • Ginseng
          • St John's Wort
          • Other Herbal/Traditional Dietary Supplements
            • Artichoke
            • Green Tea Extract
            • Starflower Oil
            • Other Other Herbal/Traditional Dietary Supplements
        • Non-Herbal Dietary Supplements
          • Calcium Supplements
          • Co-Enzyme Q10
          • Combination Non-Herbal Dietary Supplements
          • Eye Health Supplements
          • Fish Oils
            • Cod Liver Oil
            • Other Fish Oils
          • Glucosamine
          • Mineral Supplements
          • Omega-3-6-9 (Fish and Non-Fish)
          • Probiotic Supplements
          • Protein Powder
          • Royal Jelly
          • Sam-E
          • Other Non-Herbal Dietary Supplements
        • Tonics and Bottled Nutritive Drinks
        • Vitamins
          • Multivitamins
          • Single Vitamins
            • Vitamin A
            • Vitamin B
            • Vitamin C
            • Vitamin D
            • Vitamin E
            • Other Single Vitamins
      • Weight Management
        • Meal Replacement Slimming
        • OTC Obesity
        • Slimming Teas
        • Weight Loss Supplements
        • Other Slimming Products
      • Herbal/Traditional Products
        • Herbal/Traditional Analgesics
        • Herbal/Traditional Calming and Sleeping Products
        • Herbal/Traditional Cough, Cold and Allergy (Hay Fever) Remedies
        • Herbal/Traditional Digestive Remedies
        • Herbal/Traditional Medicated Skin Care
        • Herbal/Traditional Medicinal Teas
        • Herbal/Traditional Smoking Cessation Aids
        • Herbal/Traditional Paediatric Dietary Supplements
        • Herbal/Traditional Dietary Supplements
        • Herbal/Traditional Tonics and Bottled Nutritive Drinks
      • Allergy Care
        • Allergy Eye Care
        • Antihistamines/Allergy Remedies (Systemic)
        • Paediatric Allergy Remedies
        • Topical Allergy Remedies/Antihistamines
      • Paediatric Consumer Health
        • Paediatric Analgesics
          • Paediatric Acetaminophen
          • Paediatric Aspirin
          • Paediatric Combination Products - Analgesics
          • Paediatric Diclofenac
          • Paediatric Dipyrone
          • Paediatric Ibuprofen
          • Paediatric Ketoprofen
          • Paediatric Naproxen
        • Paediatric Cough, Cold and Allergy Remedies
          • Paediatric Allergy Remedies
          • Paediatric Cough/Cold Remedies
        • Paediatric Digestive Remedies
          • Paediatric Diarrhoeal Remedies
          • Paediatric Indigestion and Heartburn Remedies
          • Paediatric Laxatives
          • Paediatric Motion Sickness Remedies
        • Paediatric Medicated Skin Care
        • Nappy (Diaper) Rash Treatments
        • Paediatric Vitamins and Dietary Supplements

    Statistics Included

    Statistics Included

    For each category and subcategory you will receive the following data in Excel format:

    From Passport

    • Market sizes
    • Company shares
    • Brand shares
    • Distribution
    • Analysis by format
    • Analysis by positioning
    • Analysis by type
    • Herbal/traditional vs standard
    • Pricing
    • Smoking population - number of adult smokers
    • Smoking prevalence - % of adult population

    Market size details:

    • Retail volume
    • Retail volume % growth
    • Retail volume per capita
    • Retail value retail selling price % growth
    • Retail value retail selling price local currency, USD, EUR, GBP, CHF, JPY
    • Retail value retail selling price per capita local currency, USD, EUR, GBP, CHF, JPY
    • Retail value manufacturer selling price % growth
    • Retail value manufacturer selling price local currency, USD, EUR, GBP, CHF, JPY
    • Retail value manufacturer selling price per capita local currency, USD, EUR, GBP, CHF, JPY

    Methodology

    Methodology

    Global insight and local knowledge

    With 40 years’ experience of developed and emerging markets, Euromonitor International’s research method is built on a unique combination of specialist industry knowledge and in-country research expertise.

    This approach is what enables us to achieve our goal of building a market consensus view of size, shape and trends across the full distribution universe of each category. We factor in whichever channels are relevant, from large-scale grocery to direct sellers, from discount stores to local mom-and-pop outlets.

    Industry specialists

    Each industry we cover is managed by an Industry Manager and team of Industry Analysts who research and report on their specialist categories all year round.

    Our collaborative approach to research means that these industry teams are in constant dialogue with industry players and opinion formers. The planning of our research programmes reflects latest market trends and industry events. In completing each update project, this provides invaluable input to the testing, review and finalisation of our data.

    The specialist in-house teams bring together findings from all stages of the annual research process. They work closely with in-country analysts, assess and challenge data and exercise final editorial control over the publication of new data and analysis.

    Country and regional analysts

    Our in-country analyst network is managed by country and regional analysts in our offices around the world. Working closely with each in-country team, the regional research management team ensures that all country researchers are well schooled in best practices, from the information collected in store checks, to the dialogue we build in trade surveys. Our country analysts ensure that national reports explain the data trends and provide clear insights into the local market’s dynamics.

    In-country research network

    To deliver fresh insights every year in countries all around the world, we believe the strongest approach is to use analysts on the ground. They bring fluency in local language, physical proximity to the best sources, an ability to engage directly with local industry contacts, and an awareness of how the products and services we study are advertised, sold and consumed. These are essential parts of our ability to report incisively on these markets.

    Research Methodology

    Our research methods

    Each Euromonitor International industry report is based on a core set of research techniques:

    Desk research

    With industry events, corporate activity, trends and new product introductions tracked year round by our industry team, desk research provides a starting point for the in-country research programme. Our in-country researchers will access the following sources:

    • National statistics offices governmental and official sources
    • National and international trade press
    • National and international trade associations
    • Industry study groups and other semi-official sources
    • Company financials and annual reports
    • Broker reports
    • Online databases
    • The financial, business and mainstream press

    Accessing sources is only the first step. The ability to interpret and reconcile often conflicting information across multiple sources is a key aspect of the added value we provide.

    Store checks

    Store checks are an integral part of our methods for product industries. Carried out on the ground across a relevant mix of channels, the information gained provides first-hand insights into the products we are researching, specifically:

    • Place: We track products in all relevant channels, selective and mass, store and non-store
    • Product: What are innovations in products, pack sizes and formats?
    • Price: What are brand price variations across channels, how do private label’s prices compare to those of branded goods?
    • Promotion: What are marketing and merchandising trends, offers, discounts and tie-ins?

    Findings are cross-referenced with brand share data analysis. The results, combined with the findings of desk research, provide a strong basis for identifying key areas of questioning to take forward into our trade survey.

    Trade survey

    Interaction with global players at corporate HQ and regional levels is complemented by unique local data and insights from our in-country trade surveys around the world. Through the high profile of the Euromonitor International brand, we are able to talk directly to a wide range of sources and therefore inform our analysis with the knowledge and opinions of the leading operators in the market.

    Trade surveys allow us to:

    • Fill gaps in available published data per company
    • Generate a consensus view of the size, structure and strategic direction of the category
    • Access year-in-progress data where published sources are out of date
    • Evaluate the experts’ views on current trends and market developments

    In building our composite industry view, we engage with a variety of personnel in key players at all points of the supply chain: materials suppliers, manufacturers, distributors, retailers and service operators. We also interview desk research sources: industry associations; study groups; and third party observers from the trade and financial press.

    Our objective is to engage in conversation with trade sources in which we exchange ideas and views on the industry, sharing our work-in-progress findings on supply/demand dynamics and potential. This dialogue enhances both parties’ understanding of the local market. The scope and reach of our trade survey also serves to eliminate bias (intentional and unintentional) from any single source.

    Company analysis

    At a global level, our company research combines our mix of industry interaction and use of secondary sources such as annual accounts, broker reports, financial press and databases. From a data perspective, the aim is to build “top-down” estimates of major players’ total global and regional sales.

    At a country level, in line with local reporting requirements, we access annual accounts, national-specific company databases and local company websites. These are all invaluable sources as we build a view of each domestic player’s size and position within very specific categories of the industry.

    Forecasts

    Data projections and future performance analysis are key elements of Euromonitor International’s market intelligence. Working with historic trends of 15 years or more, a key aspect of our trade survey is to engage industry insider views of the next five years. Will volumes maintain their historic trend? Will price increases or falls of recent years continue, accelerate or slow down? Will increasing demand for one product cannibalise sales of another?

    Forecasts represent many of the essential conclusions we have reached about the current state of the market, how it works and how it behaves under different macro and micro conditions. Our written analysis will state the assumptions and the trade opinion behind whether our predictions are optimistic or pessimistic, so that clients can use our statistical forecasts with confidence.

    Data validation

    All data is subjected to an exhaustive review process, at country, regional and global levels.

    The interpretation and review of sources and data inputs forms a central part of the collaboration between industry teams and country researchers. Numbers are delivered to regional and global offices with an audit trail of sources and calculations to allow for a thorough evaluation of data sense and integrity.

    Upon completion of the country review phase, data is then reviewed on a comparative basis at regional and then at a global level. Comparative checks are carried out on per capita consumption and spending levels, growth rates, patterns of category and subcategory breakdowns and distribution of sales by channel. Top-down estimates are reviewed against bottom-up regional and global market and company sales totals.

    Where marked differences are seen between proximate country markets or ones at similar developmental levels, supplementary research is conducted in the relevant countries to confirm and/or amend those findings. This process ensures international comparability across the database, that consistent category and subcategory definitions have been used and that all data has been correctly tested. We make sure that possible discrepancies between different published sources have been reconciled and that our interpretation of opinion and expectation from each country’s trade sources has been applied to form a coherent international pattern.

    Market analysis

    Another integral part of all our research programmes is that all Euromonitor International data is accompanied by clear written analysis. From a research perspective, this explains and substantiates data findings. From a client perspective, this offers unique insights into local consumption trends, routes to market, brand preferences, channel dynamics and future trends.

    Our country level analysis also provides invaluable input into the ability of our central industry specialist teams to marry local insights with strategic conclusions on the direction of the market regionally and globally.

    my pages

    Want to find out more about this report?

    If you purchase a report that is updated in the next 60 days, we will send you the new edition of the report and the data extract FREE!